ArticleNederlands tijdschrift voor geneeskunde2014
[Clopidogrel cannot yet be exclusively for smokers].
Article in Nederlands tijdschrift voor geneeskunde, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dual antiplatelet therapy with acetylsalicylic acid and a P2Y12 receptor antagonist is the cornerstone of treatment in patients with acute coronary syndromes and patients undergoing coronary stenting. Two recent meta-analyses concluded that the efficacy of the P2Y12 receptor antagonist clopidogrel in reducing cardiovascular events is more pronounced in smokers than in non-smokers. Most probably, this is due to induction of cytochrome p450 1A2 by smoking, which accelerates conversion of clopidogrel to its active metabolite. These observations are of great interest. However, before these observations can be used to guide treatment in the clinical arena, the effect of smoking should be studied in prospective clinical trials, investigating not only its modulation of the efficacy but also of the bleeding complications of clopidogrel.
Indexed as
Identifiers
24518848W2164134879What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.